Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer
Conditions: Pancreatic Cancer Interventions: Procedure: Surgery; Drug: Camrelizumab; Biological: SJ-Neo006; Drug: Gemcitabine+Abraxane Sponsors: Jinling Hospital, China; Jiangsu Synthgene Biotechnology Co.Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 22, 2024 Category: Research Source Type: clinical trials

Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
Conditions: Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Early Stage Triple-Negative Breast Carcinoma; Locally Advanced Triple-Negative Breast Carcinoma; Metastatic Triple-Negative Breast Carcinoma; Prognostic Stage ...
Source: ClinicalTrials.gov - March 21, 2024 Category: Research Source Type: clinical trials

PREVENT HPV-Related Cancers
Conditions: Vaccine Hesitancy; HPV Vaccination; Vaccine; Uptake; Vaccination; Series Completion; Vaccine Refusal Interventions: Behavioral: PREVENT Sponsors: University of Utah; Kaiser Permanente; University of Arizona; Sea Mar Community Health Centers; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 4, 2024 Category: Research Source Type: clinical trials

Implementation of Evidence-Based Strategy (PC TEACH) for the Optimization of HPV Vaccination in Rural Primary Care
Conditions: Human Papillomavirus Infection Interventions: Other: Educational Intervention Sponsors: Roswell Park Cancer Institute; National Cancer Institute (NCI); National Institute on Minority Health and Health Disparities (NIMHD) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 13, 2024 Category: Research Source Type: clinical trials

Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
Conditions: Endometrial Cancer; Cancer of Endometrium; Carcinoma of Endometrium; Endometrial Carcinoma Interventions: Biological: AdHER2DC vaccine; Biological: Pembrolizumab; Biological: N-803; Drug: Lenvatinib; Device: PATHWAY HER2 (4B5) assay Sponsors: National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 12, 2024 Category: Research Source Type: clinical trials

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
Conditions: Metastatic Solid Cancers; Colorectal Cancer; Breast Cancer; Non-Small Cell Lung Cancer; Gastrointestinal Cancer; Ovarian Cancer; Genitourinary Cancer Interventions: Drug: Aldesleukin; Drug: Fludarabine; Drug: Cyclophosphamide; Biological: KRAS TCR-Transduced PBL; Biological: GRT-C903/GRT-R904 Sponsors: National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 12, 2024 Category: Research Source Type: clinical trials

Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls
Conditions: Cervical Intraepithelial Neoplasia; Cervical Cancer; Persistent Infection Interventions: Biological: Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli); Other: No intervention; Biological: Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) Sponsors: Xiamen University; Xiamen Innovax Biotech Co., Ltd; Center for Disease Control and Prevention, Sheyang County, Yancheng City, Jiangsu Province, China Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 6, 2024 Category: Research Source Type: clinical trials

A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer
Conditions: Breast Cancer; Breast Cancer Triple Negative Interventions: Biological: Fluzone Quadrivalent Sponsors: Rush University Medical Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 29, 2024 Category: Research Source Type: clinical trials

Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
Conditions: Squamous Cell Carcinoma of the Head and Neck; Oropharynx; Human Papillomavirus Viruses; Drug Therapy; Cancer Vaccine Interventions: Drug: Docetaxel; Drug: Cisplatin; Drug: PRGN-2009 Sponsors: National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 25, 2024 Category: Research Source Type: clinical trials

Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ
Conditions: Ductal Carcinoma in Situ Interventions: Biological: MUC1 Peptide Vaccine; Drug: Hiltonol ®; Drug: Aromatase Inhibitor Sponsors: Finn, Olivera, PhD; A Glimmer of Hope Foundation; Breast Cancer Research Foundation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 23, 2024 Category: Research Source Type: clinical trials

A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1)
Conditions: Hepatocellular Carcinoma Interventions: Biological: Peptide-based hepatocellular carcinoma vaccine IMA970A; Combination Product: Durvalumab; Other: Montanide (Adjuvant) Sponsors: National Cancer Institute, Naples Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 23, 2024 Category: Research Source Type: clinical trials

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Tumors
Conditions: Digestive System Neuroendocrine Neoplasm; Lung Neuroendocrine Neoplasm; Malignant Solid Neoplasm; Pancreatic Neuroendocrine Neoplasm Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Biological: Incomplete Freund ' ' s Adjuvant; Procedure: Magnetic Resonance Imaging; Biological: Sargramostim; Biological: SVN53-67/M57-KLH Peptide Vaccine; Drug: Temozolomide Sponsors: Roswell Park Cancer Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 11, 2024 Category: Research Source Type: clinical trials

Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil ®9 in Young Women
Conditions: Cervical Cancer; Condylomata Acuminata Interventions: Biological: Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli); Biological: Gardasil ®9 Sponsors: Xiamen Ophthalmology Center Affiliated to Xiamen University; Xiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2024 Category: Research Source Type: clinical trials

Anti-cancer Neoantigen Polypeptide Vaccine to Treat Solid Tumors
Conditions: Solid Tumor, Adult Interventions: Biological: Neoantigen Polypeptide Vaccine Sponsors: Second Affiliated Hospital of Guangzhou Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 8, 2024 Category: Research Source Type: clinical trials

Anti-cancer Neoantigen mRNA Vaccine to Treat Solid Tumors
Conditions: Solid Tumor, Adult Interventions: Biological: Neoantigen mRNA Vaccine Sponsors: Second Affiliated Hospital of Guangzhou Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 8, 2024 Category: Research Source Type: clinical trials